NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $17.12 -0.49 (-2.79%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immunome Stock (NASDAQ:IMNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunome alerts:Sign Up Key Stats Today's Range$16.78▼$18.1650-Day Range$16.47▼$26.8152-Week Range$16.41▼$30.06Volume696,805 shsAverage Volume1.37 million shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$33.85Consensus RatingModerate Buy Company Overview Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use. Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals. The company is based in the United States and conducts research and clinical development, with trials that may involve sites in multiple countries.AI Generated. May Contain Errors. Read More Immunome Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIMNM MarketRank™: 2.497015519295 of 5 starsImmunome scored higher than 50% of companies evaluated by MarketBeat, and ranked 541st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingImmunome has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmunome has a consensus price target of $33.85, representing about 94.4% upside from its current price of $17.41.Amount of Analyst CoverageImmunome has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunome's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($2.62) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.35% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 12.77, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently decreased by 6.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.05 News SentimentImmunome has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Immunome this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $334,224.00 in company stock.Percentage Held by Insiders7.21% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNM Stock News HeadlinesImmunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench2 hours ago | seekingalpha.comImmunome FY2026 Earnings Forecast Decreased by HC WainwrightNovember 14 at 2:10 AM | americanbankingnews.comDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.November 17 at 1:00 AM | TradeWins (Ad)Research Analysts Offer Predictions for Immunome Q1 EarningsNovember 13, 2026 | americanbankingnews.comImmunome (NASDAQ:IMNM) Stock Price Target Cut by Piper SandlerNovember 12, 2026 | americanbankingnews.comStifel Nicolaus Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock PriceNovember 12, 2026 | americanbankingnews.comImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 2, 2026 | businesswire.comImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid TumorsOctober 30, 2026 | businesswire.comSee More Headlines IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $21.48 at the beginning of the year. Since then, IMNM stock has decreased by 18.9% and is now trading at $17.41. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) released its earnings results on Monday, November, 9th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.14. When did Immunome IPO? Immunome (IMNM) raised $39 million in an IPO on Thursday, October 1st 2020. The company issued 3,250,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's top institutional shareholders include State Street Corp (3.95%), Goldman Sachs Group Inc. (1.21%), Nan Fung Trinity HK Ltd. (0.55%) and Marshall Wace LLP (0.44%). Insiders that own company stock include Clay B Siegall, Philip Wagenheim, Isaac Barchas, Jack Higgins, Max Rosett, Kinney Horn, Jean Jacques Bienaime, Philip Tsai and Robert Lechleider. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunome own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Broadcom (AVGO), Tesla (TSLA), Micron Technology (MU) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/09/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, IMNM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMNM CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees177Year Founded2008Price Target and Rating Average Price Target for Immunome$33.85 High Price Target$40.00 Low Price Target$23.00 Potential Upside/Downside+98.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.39 million Net MarginsN/A Pretax Margin-5,593.85% Return on Equity-51.33% Return on Assets-47.63% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio15.08 Sales & Book Value Annual Sales$6.94 million Price / Sales290.68 Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book4.44Miscellaneous Outstanding Shares118,070,000Free Float109,560,000Market Cap$2.02 billion OptionableOptionable Beta2.68 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IMNM) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.